Bioequivalence Studies of Solid Oral Dosage Forms Overview

Posted 16 August 2017 By Sharry Arora

placeholder+image The article discusses regulations and guidance for conducting bioavailability and bioequivalence studies required to obtain generic product approval across various markets. Included are comparative regulatory approaches for establishing bioequivalence of generic drugs to their corresponding reference drugs across various international jurisdictions, including Australia, Canada, EU, Japan and the US.

Share this article:

Categories: Generic drugs, Features, FDA, EMA, Health Canada, MHLW, PMDA, TGA, WHO

Tags: Bioequivalence, BE Studies, Solid Oral Dosage Forms, Bioavailability

Regulatory Exchange: Latest Updates From the Community